HRP20020940A2 - 2-acyl-indol derivatives and their use as anti-tumour agents - Google Patents

2-acyl-indol derivatives and their use as anti-tumour agents

Info

Publication number
HRP20020940A2
HRP20020940A2 HR20020940A HRP20020940A HRP20020940A2 HR P20020940 A2 HRP20020940 A2 HR P20020940A2 HR 20020940 A HR20020940 A HR 20020940A HR P20020940 A HRP20020940 A HR P20020940A HR P20020940 A2 HRP20020940 A2 HR P20020940A2
Authority
HR
Croatia
Prior art keywords
alkyl
straight
substituted
branched chain
methoxy
Prior art date
Application number
HR20020940A
Other languages
English (en)
Croatian (hr)
Inventor
Beckers Thomas
Baasner Silke
Klenner Thomas
Mahboobi Siavosh
Pongratz Herwig
Frieser Markus
Hufsky Harald
Hockemeyer J�rg
Fiebig Heinz-Herbert
Burger Angelika
B�hmer Frank-D.
Original Assignee
Baxter Healthcare S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000120852 external-priority patent/DE10020852A1/de
Priority claimed from DE2001102629 external-priority patent/DE10102629A1/de
Application filed by Baxter Healthcare S.A. filed Critical Baxter Healthcare S.A.
Publication of HRP20020940A2 publication Critical patent/HRP20020940A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HR20020940A 2000-04-28 2001-04-27 2-acyl-indol derivatives and their use as anti-tumour agents HRP20020940A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2000120852 DE10020852A1 (de) 2000-04-28 2000-04-28 2-Acryl-indolderivate und deren Verwendung als Antitumormittel
DE2001102629 DE10102629A1 (de) 2001-01-20 2001-01-20 2-Acyl-indolderivate und deren Verwendung als Antitumormittel
PCT/EP2001/004783 WO2001082909A2 (de) 2000-04-28 2001-04-27 2-acyl-indolderivate und deren verwendung als antitumormittel

Publications (1)

Publication Number Publication Date
HRP20020940A2 true HRP20020940A2 (en) 2005-02-28

Family

ID=26005501

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020940A HRP20020940A2 (en) 2000-04-28 2001-04-27 2-acyl-indol derivatives and their use as anti-tumour agents

Country Status (27)

Country Link
US (2) US20020091124A1 (cs)
EP (1) EP1276720B1 (cs)
JP (1) JP2004501092A (cs)
KR (1) KR20030024661A (cs)
CN (1) CN1286810C (cs)
AR (1) AR029915A1 (cs)
AT (1) ATE348805T1 (cs)
AU (1) AU783459B2 (cs)
BG (1) BG107309A (cs)
BR (1) BR0110414A (cs)
CA (1) CA2407677A1 (cs)
CZ (1) CZ20023544A3 (cs)
DE (1) DE50111690D1 (cs)
EE (1) EE200200607A (cs)
GE (1) GEP20063751B (cs)
HK (1) HK1054549B (cs)
HR (1) HRP20020940A2 (cs)
HU (1) HUP0300480A3 (cs)
IL (1) IL152477A0 (cs)
IS (1) IS6594A (cs)
MX (1) MXPA02010627A (cs)
NO (1) NO20025150L (cs)
NZ (1) NZ522246A (cs)
PL (1) PL358877A1 (cs)
RU (1) RU2002132253A (cs)
SK (1) SK15432002A3 (cs)
WO (1) WO2001082909A2 (cs)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0111230A (pt) 2000-05-31 2003-06-10 Astrazeneca Ab Composto, e, uso e processo para a preparação do mesmo
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
DE10152306A1 (de) * 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
US7125906B2 (en) 2002-04-03 2006-10-24 Astrazeneca Ab Indole derivatives having anti-angiogenetic activity
TW200400177A (en) 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
SE0300908D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
CN1902193B (zh) * 2003-12-04 2011-07-13 沃泰克斯药物股份有限公司 可用作蛋白激酶抑制剂的喹喔啉
MXPA06014471A (es) 2004-06-09 2007-03-21 Glaxo Group Ltd Derivados de pirrolopiridina.
BRPI0517549A (pt) * 2004-10-05 2008-10-14 Merz Pharma Gmbh & Co Kgaa novas propenonas cìclicas e acìclicas para o tratamento de distúrbios do snc
WO2006084338A1 (en) * 2005-02-14 2006-08-17 Bionomics Limited Novel tubulin polymerisation inhibitors
KR20080087070A (ko) * 2005-05-20 2008-09-30 알란토스 파마슈티컬즈 홀딩, 인코포레이티드 피리미딘 또는 트리아진 융합된 비시클릭 메탈로프로테아제억제제
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
FR2950053B1 (fr) * 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
WO2014033497A1 (en) * 2012-08-27 2014-03-06 Centre National De La Recherche Scientifique 5-azaindole compounds with anticancer and antiangiogenic activities
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
JP6820854B2 (ja) * 2015-01-18 2021-01-27 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｍａｐ４ｋ４（ｈｇｋ）インヒビター
CN104945376B (zh) * 2015-07-09 2017-03-15 安徽理工大学 一种3‑芳酰基吲哚化合物的合成方法
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
CN107722013B (zh) * 2016-08-11 2021-01-12 中国科学院上海药物研究所 去氮嘌呤类化合物及其药物组合物、制备方法和用途
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
CN116262721A (zh) * 2023-01-12 2023-06-16 浙江师范大学 一种二氢吲哚衍生物及吲哚衍生物的制备方法及产品

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660430A (en) * 1969-11-04 1972-05-02 American Home Prod 2-substituted-3-arylindoles
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
DK3375A (cs) * 1974-01-25 1975-09-15 Ciba Geigy Ag
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
EP0938474B1 (en) * 1996-09-12 2005-11-23 Auckland Uniservices Limited Cyclopropylindole compounds and their use as prodrugs
AP9801302A0 (en) * 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..

Also Published As

Publication number Publication date
HUP0300480A2 (hu) 2003-06-28
CN1431997A (zh) 2003-07-23
CZ20023544A3 (cs) 2004-07-14
EE200200607A (et) 2004-04-15
AU783459B2 (en) 2005-10-27
WO2001082909A2 (de) 2001-11-08
MXPA02010627A (es) 2004-05-17
ATE348805T1 (de) 2007-01-15
NO20025150L (no) 2002-12-16
BR0110414A (pt) 2003-02-11
PL358877A1 (en) 2004-08-23
KR20030024661A (ko) 2003-03-26
HK1054549A1 (en) 2003-12-05
GEP20063751B (en) 2006-02-27
US20030158216A1 (en) 2003-08-21
US20020091124A1 (en) 2002-07-11
HK1054549B (zh) 2007-02-23
CA2407677A1 (en) 2002-10-28
IL152477A0 (en) 2003-05-29
SK15432002A3 (sk) 2004-01-08
IS6594A (is) 2002-10-25
JP2004501092A (ja) 2004-01-15
CN1286810C (zh) 2006-11-29
EP1276720A2 (de) 2003-01-22
RU2002132253A (ru) 2004-07-10
BG107309A (bg) 2003-09-30
AR029915A1 (es) 2003-07-23
DE50111690D1 (de) 2007-02-01
WO2001082909A3 (de) 2002-03-14
NO20025150D0 (no) 2002-10-25
AU6898401A (en) 2001-11-12
NZ522246A (en) 2006-01-27
EP1276720B1 (de) 2006-12-20
HUP0300480A3 (en) 2006-04-28

Similar Documents

Publication Publication Date Title
HRP20020940A2 (en) 2-acyl-indol derivatives and their use as anti-tumour agents
TWI520950B (zh) Ｍｄｍ２／４及ｐ５３交互作用抑制劑之結晶型
US9597325B2 (en) Inhibitors of late SV40 factor (LSF) as cancer chemotherapeutics
TW201705955A (zh) 包含吡咯啶－２，５－二酮ｉｄｏ１抑制劑及抗－ｐｄ１／抗－ｐｄ－ｌ１抗體之組合療法
CN101365703A (zh) 杂烷基连接的嘧啶衍生物
EP3632908A1 (en) Inhibitors of the yap/taz-tead interaction and their use in the treatment of cancer
CA2652307A1 (en) Compositions and methods for modulating gated ion channels
CA3047684A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
CA2782555A1 (en) 3-(indolyl)-or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
EP4107157A1 (en) Setd2 inhibitors and related methods and uses, including combination therapies
CN116234797A (zh) 用于治疗癌症的tead的杂环抑制剂
AU2008246947B2 (en) Aminoalkoxy aryl sulfonamide compounds and their use as 5-HT6 ligands
JP2005516895A (ja) 腫瘍の治療のための２−アシルインドールの使用
EP3468950A1 (en) Aza-tanshinone derivatives, process for their preparation and their use in therapy
CN109071457A (zh) 吲哚胺2,3-双加氧酶的抑制剂
JPWO2015182625A1 (ja) Ｒａｓ活性阻害薬及びその用途
US11053230B2 (en) 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase
JPWO2021168313A5 (cs)
HK40084091A (en) Setd2 inhibitors and related methods and uses, including combination therapies
DE10020852A1 (de) 2-Acryl-indolderivate und deren Verwendung als Antitumormittel
DE10102629A1 (de) 2-Acyl-indolderivate und deren Verwendung als Antitumormittel
HK1106141A (en) Diphenyl-indol-2-on compounds and their use in the treatment of cancer

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060811

Year of fee payment: 6

OBST Application withdrawn